broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K62008436-001-23-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.334664 | 5.172525 | 0.6394 | 0.686948 | 0.006496 | 0.008046 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000988 |
BRD-K62200014-003-10-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.317309 | 5.591615 | 0.275609 | 1 | 0.018033 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000988 |
BRD-K62627508-001-01-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.736636 | -1.739855 | -0.048105 | 0.874779 | 0.061549 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000988 |
BRD-K63504947-001-14-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.888866 | -0.591332 | -0.179036 | 0.929319 | 0.349605 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000988 |
BRD-K63712959-001-01-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.257894 | 3.116515 | 0.088172 | 1 | 0.036495 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000988 |
BRD-K64052750-001-22-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.711448 | 0.706997 | 0.330224 | 0.819837 | 0.021305 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000988 |
BRD-K64881305-001-03-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.523863 | 0.455081 | 0.309405 | 0.750056 | 0.057745 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000988 |
BRD-K66175015-001-12-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.036071 | 0.456616 | 0.652752 | 0.667941 | 0.534027 | 0.629186 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000988 |
BRD-K67844266-003-01-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.515881 | 1.107938 | -0.111279 | 0.948465 | 5.029672 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000988 |
BRD-K69001009-001-02-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.89924 | 3.584459 | 0.084383 | 0.949593 | 0.077903 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000988 |
BRD-K69694239-001-02-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.091898 | 3.836021 | 0.659502 | 0.827507 | 0.515219 | 0.543231 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000988 |
BRD-K69776681-001-03-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.238107 | 1.398484 | 0.826864 | 0.495222 | 0.016013 | 0.025428 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000988 |
BRD-K70301465-001-05-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.800733 | 3.554571 | 0.109867 | 0.854024 | 0.008175 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000988 |
BRD-K73838513-003-05-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.566 | -0.258244 | -0.178759 | 0.786822 | 0.066967 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000988 |
BRD-K74514084-003-09-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.925322 | -0.195967 | -0.099895 | 0.947833 | 7.684812 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000988 |
BRD-K75009076-001-02-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.116917 | 0.955598 | 0.66128 | 0.735504 | 0.583632 | 0.771243 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000988 |
BRD-K76210423-001-01-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.146157 | 0.025894 | -0.030379 | 1 | 0.000277 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000988 |
BRD-K76239644-001-02-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.585482 | 0.131888 | 0.058724 | 0.799336 | 0.128649 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000988 |
BRD-K76674262-001-03-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.172786 | 0.640875 | 0.59589 | 0.679463 | 0.260285 | 0.504393 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000988 |
BRD-K76908866-001-07-6 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.560579 | 3.06532 | 0.637481 | 0.819333 | 0.18499 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000988 |
BRD-K77625799-001-07-7 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.450739 | 0.049541 | -0.02619 | 0.720583 | 0.038512 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000988 |
BRD-K78431006-001-15-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.777526 | -3.722853 | 0.104842 | 0.880775 | 0.110662 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000988 |
BRD-K81016934-001-02-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.365995 | -0.29179 | -0.101476 | 0.892426 | 0.000164 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000988 |
BRD-K81418486-001-44-2 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.104847 | 3.788527 | 0.642578 | 0.866985 | 2.367059 | 2.518804 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000988 |
BRD-K81473043-001-19-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.782617 | 2.122717 | 0.459957 | 1 | 0.272082 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000988 |
BRD-K82135108-001-04-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.16747 | -0.129505 | -0.086943 | 1 | 0.000775 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000988 |
BRD-K82746043-001-19-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.099406 | 3.240786 | 0.683905 | 0.897199 | 0.981499 | 1.050981 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000988 |
BRD-K82818427-001-04-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.940432 | -1.846125 | 0.034122 | 0.956214 | 0.768118 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000988 |
BRD-K83029223-001-01-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.36561 | 1.980488 | 0.635161 | 0.649567 | 0.002934 | 0.005697 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000988 |
BRD-K85402309-043-01-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 2.300538 | 0.243375 | -0.029283 | 1 | 2,173,069.080249 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000988 |
BRD-K85606544-001-09-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.713434 | 0.269728 | -0.108477 | 0.952464 | 61.45335 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000988 |
BRD-K86118762-001-01-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.774328 | -9.039687 | 0.216523 | 0.905936 | 0.078196 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000988 |
BRD-K86972824-001-01-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.14101 | -0.002321 | -0.010126 | 1 | 38,327,138,703,449,367,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000988 |
BRD-K87737963-001-06-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | -0.250243 | 1.581966 | 0.0517 | 0.976756 | 20.141318 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000988 |
BRD-K87782578-001-01-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.708222 | -0.127291 | -0.070145 | 0.854938 | 0.071246 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000988 |
BRD-K87909389-003-03-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.145689 | 2.766568 | 0.412408 | 0.869436 | 0.708856 | 0.802836 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000988 |
BRD-K88510285-001-17-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.28856 | 5.737426 | 0.702757 | 0.671841 | 0.02848 | 0.033089 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000988 |
BRD-K89014967-001-04-3 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.442008 | 0.826712 | 0.168523 | 1 | 0.110554 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000988 |
BRD-K92441787-001-04-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.869089 | -9.184457 | 0.230426 | 0.934522 | 0.078233 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000988 |
BRD-K92723993-001-17-4 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 23.843238 | 13.564383 | -0.007712 | 1 | 37,105,425.501406 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000988 |
BRD-K95142244-001-01-5 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.665514 | 0.336804 | 0.121356 | 0.859708 | 0.251452 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000988 |
BRD-K96123349-236-02-8 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.427104 | 0.379916 | 0.138192 | 0.744334 | 0.160397 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000988 |
BRD-K98572433-001-02-9 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.869811 | -0.616347 | 0.075101 | 0.932335 | 0.09654 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000988 |
BRD-K99113996-001-02-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.023399 | 1.112006 | -0.050424 | 1 | 0.155419 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000988 |
BRD-K99616396-001-05-1 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 0.34596 | -1.351226 | 0.097434 | 0.947594 | 0.000965 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000988 |
BRD-K99749624-001-07-0 | ACH-000988 | MFE319_ENDOMETRIUM | MTS010 | 1 | 1.419145 | -0.164374 | -0.003471 | 1 | 0.00003 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000988 |
BRD-A25234499-001-19-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.096421 | -2.908357 | 0.052571 | 1 | 0.200941 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000990 |
BRD-A70858459-001-01-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.637174 | -0.366417 | 0.116264 | 0.896454 | 0.003563 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000990 |
BRD-A74914197-001-02-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.914044 | 1.217215 | 0.003562 | 0.945237 | 0.001276 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000990 |
BRD-K02113016-001-19-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.180209 | 0.4612 | 0.08076 | 1 | 0.135848 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000990 |
BRD-K02130563-001-11-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.095104 | 1.075815 | 0.633965 | 0.686079 | 0.353482 | 0.430068 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000990 |
BRD-K03390685-001-01-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.873403 | 0.129711 | -0.025865 | 0.939766 | 0.168944 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000990 |
BRD-K03406345-001-21-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.078833 | -0.121147 | -0.164848 | 1 | 2.348773 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000990 |
BRD-K03449891-001-08-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.903263 | -0.025498 | -0.003017 | 0.955504 | 0.000072 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000990 |
BRD-K03765900-001-01-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.009423 | 1.586309 | 0.246977 | 0.920703 | 5.714711 | 5.783662 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000990 |
BRD-K05804044-001-18-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.692972 | 1.901859 | 0.288091 | 0.867098 | 0.149858 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000990 |
BRD-K06814349-304-02-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.017834 | -0.064947 | -0.007602 | 1 | 1,971,161.269563 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000990 |
BRD-K08109215-001-06-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 2.000852 | 1.020918 | 0.66186 | 1 | 7.968144 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000990 |
BRD-K08542803-001-02-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.052323 | 6.845979 | 0.579682 | 0.81938 | 1.572962 | 1.598573 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000990 |
BRD-K08547377-001-04-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.166241 | -0.917597 | 0.061553 | 1 | 0.014311 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000990 |
BRD-K08799216-001-05-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.283939 | 9.379905 | 0.447434 | 0.971388 | 6.805034 | 7.441742 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000990 |
BRD-K09951645-001-11-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.10655 | -0.046141 | 0.005485 | 1 | 0.583293 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000990 |
BRD-K11267252-001-05-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 56.961884 | 0.934079 | 0.089277 | 1 | 4,511.207476 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000990 |
BRD-K11630072-001-13-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.834453 | -2.842279 | 0.21025 | 0.936357 | 0.025445 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000990 |
BRD-K12184916-001-19-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.565938 | 10.563228 | 0.481912 | 0.661128 | 0.004989 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000990 |
BRD-K12343256-001-14-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.784016 | 5.706183 | 0.341928 | 0.830645 | 0.004957 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000990 |
BRD-K13049116-001-04-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.801265 | -1.00208 | -0.153275 | 0.983216 | 0.000777 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000990 |
BRD-K13390322-001-06-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.166812 | 15.022644 | 0.611137 | 0.830522 | 1.388985 | 1.427011 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000990 |
BRD-K13514097-001-04-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.970657 | -2.522793 | -0.034234 | 0.977717 | 0.969261 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000990 |
BRD-K13662825-001-07-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.100382 | 1.797281 | 0.763407 | 0.55231 | 0.02001 | 0.022667 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000990 |
BRD-K14109347-001-03-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.758285 | -0.317201 | -0.003818 | 0.89252 | 0.033942 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000990 |
BRD-K15179879-001-03-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.09654 | 10.451964 | 0.862755 | 0.418611 | 0.0194 | 0.019802 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000990 |
BRD-K15600710-066-05-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.424461 | 4.861764 | 0.481659 | 0.909297 | 2.127501 | 3.138319 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000990 |
BRD-K16730910-001-10-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | -0.526028 | 1.450838 | 0.43601 | 0.93409 | 11.305009 | 6.88788 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000990 |
BRD-K17555800-003-02-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.982934 | 0.031473 | -0.005065 | 0.991459 | 0.073592 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000990 |
BRD-K17610631-001-03-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.594487 | 2.807063 | 0.230926 | 0.868023 | 0.411598 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000990 |
BRD-K17743125-001-08-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.329068 | 4.220106 | 0.618744 | 0.917602 | 3.041351 | 3.922085 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000990 |
BRD-K17894950-001-14-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.031111 | 0.151579 | -0.022659 | 1 | 0.639116 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000990 |
BRD-K18961567-001-01-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.902964 | -1.077675 | -0.045744 | 0.920948 | 1.911649 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000990 |
BRD-K19540840-001-09-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.611183 | 0.373507 | 0.220362 | 0.759407 | 0.015356 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000990 |
BRD-K19687926-001-04-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.891339 | -0.88855 | 0.106129 | 0.940757 | 0.122607 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000990 |
BRD-K19796430-001-05-6 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.746201 | 0.068578 | -0.116499 | 0.864724 | 0.011161 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000990 |
BRD-K22064724-001-01-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.099551 | 7.25133 | 0.841061 | 0.848182 | 1.947125 | 2.007664 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000990 |
BRD-K22822991-001-02-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.859038 | 0.613113 | 0.036345 | 0.925313 | 0.056664 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000990 |
BRD-K23228615-001-02-8 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.806891 | -0.536992 | 0.006571 | 0.98944 | 0.000078 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000990 |
BRD-K23984367-001-07-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.674414 | 8.527862 | 0.695048 | 0.929783 | 1.233238 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000990 |
BRD-K26026438-001-01-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.869667 | 1.089103 | 0.176782 | 0.905518 | 0.008365 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000990 |
BRD-K26657438-001-15-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.826897 | 8.855349 | 0.052902 | 0.961706 | 1.168457 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000990 |
BRD-K28822270-001-03-7 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.359527 | 1.275223 | 0.526179 | 0.898729 | 2.542091 | 6.879676 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000990 |
BRD-K29905972-001-06-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.98865 | -1.037675 | -0.051836 | 0.995991 | 0.018295 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000990 |
BRD-K30577245-001-05-0 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.731033 | 3.57736 | 0.037407 | 0.904942 | 0.020242 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000990 |
BRD-K31698212-001-02-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.831867 | 7.445668 | 0.137506 | 0.918475 | 0.090442 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000990 |
BRD-K31928526-001-02-1 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 1.224042 | -0.164871 | -0.052842 | 1 | 14.436198 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000990 |
BRD-K33379087-001-07-5 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.676661 | -0.171683 | 0.019173 | 0.839935 | 0.069115 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000990 |
BRD-K33610132-001-02-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.867077 | -4.919886 | 0.145102 | 0.924119 | 0.155359 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000990 |
BRD-K33622447-066-01-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.422936 | 5.961344 | 0.747332 | 0.857866 | 0.916016 | 1.253526 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000990 |
BRD-K35520305-001-16-9 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.947241 | 0.003551 | -0.004032 | 0.973278 | 0.000052 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000990 |
BRD-K36627727-001-05-4 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 48.056541 | 0.944211 | -0.135812 | 1 | 26,783,618.961487 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000990 |
BRD-K36788280-001-01-2 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.548199 | 0.18499 | -0.528253 | 0.718413 | 0.004308 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000990 |
BRD-K38332599-001-01-3 | ACH-000990 | HEC108_ENDOMETRIUM | MTS010 | 1 | 0.604042 | 1.028471 | 0.573285 | 0.829166 | 0.153421 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000990 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.